Your session is about to expire
← Back to Search
KUS121 low dose group for Central Retinal Artery Occlusion (GION Trial)
GION Trial Summary
"This trial is investigating the effectiveness and safety of KUS121 injection in patients with a sudden vision loss condition called central retinal artery occlusion, for which there is currently no proven treatment."
GION Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.GION Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the upper limit of participants enrolled in this medical study?
"Indeed, clinicaltrials.gov indicates that this study is presently seeking volunteers. This trial was initially posted on the 1st of April 2024 and last revised on the same day. Enrollment aims to recruit a total of 75 participants distributed among four distinct locations."
What is the safety profile of the low-dose group receiving KUS121 in individuals?
"Our assessment at Power suggests that the safety rating for the low-dose group of KUS121 is a 2 on our scale. This score aligns with being in Phase 2, indicating some evidence supporting safety without sufficient data backing efficacy."
Are new participants being enrolled in this study at this time?
"Indeed, the information from clinicaltrials.gov indicates that this trial is currently seeking participants. The trial was initially posted on April 1st, 2024 and underwent its last revision on the same day. This study aims to recruit 75 individuals across four distinct sites."
Are multiple medical centers in Canada conducting this research trial?
"This clinical study is operational at 4 different sites, with clinics located in Bellaire, Huntington Beach, Austin and several other undisclosed locations. Opting for the nearest clinic will reduce travel constraints post-enrollment."
Share this study with friends
Copy Link
Messenger